# Cannabidiol in the Treatment of Opioid Use Disorder

> **NCT06206291** · PHASE2 · COMPLETED · sponsor: **Yasmin Hurd** · enrollment: 141 (actual)

## Conditions studied

- Opioid Use Disorder

## Interventions

- **DRUG:** Placebo
- **DRUG:** Cannabidiol (CBD) 200mg
- **DRUG:** Cannabidiol (CBD) 400mg

## Key facts

- **NCT ID:** NCT06206291
- **Lead sponsor:** Yasmin Hurd
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-04
- **Primary completion:** 2024-12-04
- **Final completion:** 2024-12-04
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2024-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06206291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06206291, "Cannabidiol in the Treatment of Opioid Use Disorder". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06206291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*